Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma  

作　　者：Jia-Ni Wang Quan-Hui Qiao Xing-Sheng Hu Yu-Tao Liu Zhi-Jie Wang Jian-Chun Duan Yu Feng Hao-Hua Zhu 

机构地区：[1]Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [2]Department of Medical Oncology,Gongyi People’s Hospital,Gongyi,Henan 451200,China

出　　处：《Chinese Medical Journal》2021年第17期2119-2121,共3页中华医学杂志（英文版）

摘　　要：To the Editor:Pemetrexed plus platinum(cisplatin or carboplatin)chemotherapy doublets are widely recommended as the standard first-line treatment for non-small cell lung cancer(NSCLC)with no identified genetic mutations.[1]However,their efficiency has been confirmed with a median survival of approximately 10.2 to 13.0 months and a 5-year survival rate of 13%to 15%.Initial chemotherapy with pemetrexed has been confirmed as an effective regimen for advanced lung adenocarcinoma without specific genetic biomarker predicting the benefit of pemetrexed efficacy.[2]Patients treated with pemetrexedbased regimens can also receive a single agent as maintenance treatment after the induction chemotherapy.

关 键 词：CHEMOTHERAPY PEMETREXED ADENOCARCINOMA 

分 类 号：R734.2[医药卫生—肿瘤]